Siren Biotechnology and Catalent Inc. entered a strategic partnership to support the development and manufacturing of Siren Biotechnology's AAV immuno-gene therapies. Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology's adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent will further support process optimization at its process and clinical development center in Baltimore, MD.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.32 USD | +0.29% | +2.66% | +25.26% |
01:21pm | Barclays Adjusts Catalent Price Target to $63 From $47 | MT |
06-24 | Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.26% | 10.16B | |
+55.17% | 811B | |
+43.62% | 640B | |
-7.42% | 353B | |
+17.73% | 333B | |
+8.86% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.35% | 168B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer